Background:Serum uric acid-to-creatinine ratio (SUA/Cr) is a useful index of renal function-normalized serum uric acid (SUA), which reflects endogenous SUA levels more precisely than SUA. SUA/Cr relates to disease activity and prognosis of several metabolic disorders, like metabolic syndrome, non-alcoholic fatty liver disease, and diabetes mellitus [1]. Besides, the urine uric acid-to-creatinine ratio is valuable for the assessment of gout [2]. However, no study focuses on the relationship between SUA/Cr and gout.Objectives:We aimed to investigate the relationship between SUA/Cr and the features of demography, manifestations, laboratory tests, and urate-lowering therapies (ULTs) in gout patients.Methods:This cross-sectional study was performed from December 2015 to February 2020. Medical records of gout patients who were regularly undergone follow-up were evaluated. Characteristics of gout patients, included age, gender, the duration of gout, body mass index (BMI), tophus, complications, the number of flares, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), were recorded. Complications were defined as hypertension, coronary artery diseases, diabetes, strokes, and/or metabolic diseases. Information about ULT was obtained as well. The Spearman correlation analysis was used to assess the relationship between continuous variables. The Mann-Whiney U test or Kruskal-Wallis test was employed to compare the differences of SUA/Cr between genders, ULTs, and whether patients had tophus or complications. A P<0.05 was considered as statistically significant.Results:(1) Of 627 gout patients who were involved, 608 (96.97%) were male. Their median (range) of age and the duration of gout were 30.00 (51.00) years and 5.00 (30.00) years, respectively. (2) SUA/Cr negatively correlated with age (r=-0.71, P<0.05). SUA/Cr was similar between genders. (3) SUA/Cr positively correlated with BMI (r=0.14, P<0.05), while the coefficient correlation for the duration of gout and the number of flares did not reach statistically significant (P>0.05). SUA/Cr was significantly higher in patients with complications than the others [5.56 (9.26) vs. 4.16 (8.34), P<0.05], but whether patients with tophus or not shared similar SUA/Cr. (4) CRP and ESR did not associate with SUA/Cr (P>0.05). (5) Patients with combination therapy with xanthine oxidase inhibitor and uricosuric agent had a lower SUA/Cr compared with those who used ULTs monotherapy [3.44 (7.10) vs. 4.53 (7.91), P<0.05].Conclusion:SUA/Cr relates to some features of gout, so it may be a potential marker for its assessment.References:[1]Medicine (Baltimore) 2020;99(17):e19959.[2]J Korean Med Sci 2020;35(13):e95.Disclosure of Interests:None declared.